The September programme drew a full room to Foley Hoag Seaport for a panel on unconventional capital in healthcare. Five practitioners; three drawn from angel groups and family foundations, a former public company chief executive now advising early stage biotech, and a moderator with four decades of emerging company legal work. The following notes are drawn from the discussion.
The office that does not have to say yes
Family offices are neither angels nor venture capitalists nor private equity, and the difference matters most in what they are permitted to ignore. A fund faces a clock. The family office faces none. John Parker's last two Charles Hood Foundation cheques went to companies he had watched for more than four years before writing them. Boston hosts one of the world's densest concentrations of multifamily offices; most of them do not read cold decks and will telephone the founders they want.
For orientation, the working definitions given from the stage. The accredited investor threshold sits at roughly one million dollars in net worth. Ultra high net worth begins closer to twenty million.
We don't have to put our money to work. That's different than a venture capital fund. We tend to watch companies for a very long time. John Parker · Springhood Ventures & Charles Hood Foundation
Getting the meeting in the first place
Every panellist gave the same answer. Warm introductions are effectively the only route in. The room, they said, drowns in unread pitches that arrive over the transom, and even those with a personal referral wait months for a response.
Founders looking for a way to earn one have three practical options. Study a family's philanthropy carefully enough to find genuine overlap with the science; food allergy, oncology, cardiology, paediatric health. Attend the educational sessions that private banks and their wealth arms run for clients, which are in fact educational and not selling occasions. And use PitchBook to work backward from the cap tables of comparable companies to the investors who wrote the earlier cheques.
One panellist offered a rule that would be familiar in Tokyo. Do not ask for a business card. If the investor wants you to have one, the card will appear.
Beyond the deck, an unsentimental question
The opening question a family office tends to ask, according to Hession, is short. What is different this time? Many of the people asking it were burned in life sciences a decade ago and are looking for a structured answer that acknowledges as much.
What the panel would like to see in a deck, and rarely does, is a milestone plan drawn as a Gantt chart, with scientific, clinical and product milestones tied to specific dollar figures, and a plainly written use of proceeds for the round on the table. Regulatory costs and trial spend belong in the plan, not in the appendix. Strategic conversations already in motion; a pilot with a pharma company, a licensing discussion, a signed letter of intent; serve as the outside validation that both family offices and venture funds are quietly looking for.
Jess McLear put it more directly. A founder who has not mapped the regulatory and trial spend a family office already knows will be required does not receive a second meeting.
Follow on financing, still the largest risk on the table
Hession named follow on financing risk as the single greatest risk he has watched play out across the past decade of angel investing. The consequence is that fundraising has become a continuous activity for the founder. The next round should already be in motion by the time the current one closes.
The panel's remedy was practical. Hire a fractional chief financial officer or an advisor who has run the whole capital stack several times, and treat the sequence of rounds as a single plan rather than as a series of surprises.
Fundraising right now is almost continuous. As you're raising your one round, you should already be thinking of your next. Josko Silobrcic · Hub Angels
The Alzheimer's Moonshot question, and what it exposed
An audience member working on the Alzheimer's Moonshot flagged the current dynamic without decoration. The National Institutes of Health cuts have removed roughly three hundred and fifty million dollars of anticipated funding, and the venture firms that had been pacing themselves against that pipeline have moved into reserve mode. Founders who would once have bridged themselves on non dilutive research money are now competing for the same venture dollars as everyone else, and the qualifying bar has moved higher.
Cheryl Blanchard added a second consequence. Boston venture capitalists have shifted toward the later stages, wanting a programme ready to file an IND or a company with Phase 1 clinical data in hand before they will engage. That has opened the door to a wave of licensing and partnership activity with Chinese biotech companies, which have reached those clinical stages faster and are willing to deal.
A figure worth remembering, from Hession by way of PitchBook. The national average life sciences seed round sits at around four and a half million dollars. Hub Angels, however, has not seen a preseed or seed cheque in Boston clear two million in three years. Read the reports carefully; the averages will mislead you.
Artificial intelligence, minus the label
Silobrcic was direct on the AI label. Applying it to what is in fact traditional business analytics or ordinary rules based processing does not help a raise and can actively hurt one. Most of Hub Angels' recent commitments are in businesses that use artificial intelligence in some form. Separating genuine capability from marketing residue, however, is a live problem for the room and, on the evidence, for the market as a whole.
Hub Angels' three areas of active investment interest, for those wondering where the fund is currently spending time. Healthcare services that use artificial intelligence in the workflow. Diagnostics. And drug discovery tools. Biotech capital itself sits outside the fund's mandate.
The exit, in one number
Roughly ninety five percent of liquidity events in life sciences are trade sales. Initial public offerings account for the remaining five percent or so. For an angel investor, that ratio is the base case for how a return actually arrives, and the panel treated the initial public offering as the exception it is. Founders were advised to plan around the trade sale from the beginning, and to understand which strategic buyers might, five or seven years out, actually write the cheque.
95% of life science liquidity events are M&A. IPO is not the end game for angel investors. John Hession · Hub Angels Fund VII Advisory Board
